Glucuronidation in therapeutic drug monitoring

被引:46
|
作者
Shipkova, M
Wieland, E
机构
[1] Klinikum Stuttgart, Zentralinst Klin Chem & Laboratoriumsmed, D-70174 Stuttgart, Germany
[2] Klinikum Stuttgart, Dept Clin Chem & Lab Med, D-70174 Stuttgart, Germany
关键词
glucuronide metabolites; drug monitoring; UGT polymorphisms; drug pharmacokinetic; pharmacologically active metabolites; toxicity;
D O I
10.1016/j.cccn.2005.02.023
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Glucuronidation is a major drug-metabolizing reaction in humans. A pharmacological effect of glucuronide metabolites is frequently neglected and the value of therapeutic drug Monitoring has been questioned, However, this may not always be true. Methods: In this review the impact of glucuronidation on therapeutic drug monitoring, has been evaluated on the basis of a literature search and experience from the own laboratory. Results: The potential role of monitoring glucuronide metabolite concentrations to optimize therapeutic Outcome is addressed on the basis of selected examples of drugs which are metabolized to biologically active reactive glucuronides, Furthermore indirect effects of glucuronide metabolites on parent drug. pharmacokinetics are presented. In addition, factors that may modulate the disposition of these metabolites (e.g. genetic polymorphisms, disease processes, age, and drug drug interactions) are briefly mentioned and their relevance for the clinical Situation is critically discussed. Conclusion: Glucuronide metabolites can have indirect as well as direct pharmacological or toxicological effects. Although convincing evidence to support the introduction Of glucuronide monitoring into clinical practice is currently missing, measurement of glucuronide concentrations may be advantageous in specific situations, If the glucuronide metabolite has an indirect effect on the pharmacokinetics of the parent compound, monitoring of the parent drug may be considered. Furthermore pharmacogenetic approaches considering uridine diphosphate (UDP) glucuronosyltransferases polymorphisms may become useful in the future to optimize therapy with drugs Subject to glucuronidation. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:2 / 23
页数:22
相关论文
共 50 条
  • [31] Therapeutic drug monitoring in highly active antiretroviral therapy
    Liu, Xia
    Ma, Qing
    Zhang, Fujie
    EXPERT OPINION ON DRUG SAFETY, 2010, 9 (05) : 743 - 758
  • [32] Example of active therapeutic drug-monitoring: Itraconazole
    Levron, JC
    LeMoing, JP
    Chwetzoff, E
    THERAPIE, 1996, 51 (05): : 502 - 506
  • [33] Therapeutic Drug Monitoring in Practice for Inflammatory Bowel Disease
    Megna B.W.
    Vaughn B.P.
    Current Gastroenterology Reports, 2022, 24 (12) : 191 - 200
  • [34] Therapeutic drug monitoring in HIV treatment: A literature review
    Wertheimer, Benjamin Z.
    Freedberg, Kenneth A.
    Walensky, Rochelle P.
    Yazdanapah, Yazdan
    Losina, Elena
    HIV CLINICAL TRIALS, 2006, 7 (02): : 59 - 69
  • [35] Therapeutic drug monitoring in patients with inflammatory bowel disease
    Yarur, Andres J.
    Abreu, Maria T.
    Deshpande, Amar R.
    Kerman, David H.
    Sussman, Daniel A.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (13) : 3475 - 3484
  • [36] Species differences in drug glucuronidation: Humanized UDP-glucuronosyltransferase 1 mice and their application for predicting drug glucuronidation and drug-induced toxicity in humans
    Fujiwara, Ryoichi
    Yoda, Emiko
    Tukey, Robert H.
    DRUG METABOLISM AND PHARMACOKINETICS, 2018, 33 (01) : 9 - 16
  • [37] Evaluation of voriconazole therapeutic drug monitoring in malignant hematology patients
    Flores, Jerome
    Flank, Jacqueline
    Polito, Samantha
    Dhillon, Patwant
    Pang, Ian
    Ho, Lina
    Yee, Karen W. L.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024,
  • [38] Therapeutic drug monitoring of vancomycin in severe sepsis and septic shock
    Vazquez, M.
    Fagiolino, R.
    Boronat, A.
    Buroni, M.
    Maldonado, C.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2008, 46 (03) : 140 - 145
  • [39] OPTIMAL EXPERIMENTAL-DESIGN AND THERAPEUTIC DRUG-MONITORING
    KULCSAR, C
    PRONZATO, L
    WALTER, E
    INTERNATIONAL JOURNAL OF BIO-MEDICAL COMPUTING, 1994, 36 (1-2): : 95 - 101
  • [40] Determination of Ciprofloxacin in Dried Blood Spots for Therapeutic Drug Monitoring
    Al-Ghazawi, Mutasim
    AbuRuz, Salah
    CHROMATOGRAPHIA, 2010, 71 (11-12) : 999 - 1005